Form 4 for HUMA Humacyte, Inc.
Accepted 2023-10-10 00:00:00 ET · period of report 2023-10-10 · accession 0001818382-23-000153 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-10 | 2023-10-10 | HUMA | Niklason Laura E | Pres, CEO, Dir | M - OptEx | $1.19 | +114.4K | 1.38M | +9% | +$136.2K |
| D | 2023-10-10 | 2023-10-10 | HUMA | Niklason Laura E | Pres, CEO, Dir | M - OptEx | $0.00 | -114.4K | 48.2K | -70% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-10 | M | A | 114,420 | $1.19 | 1,384,660 | D | — | — | |
| 2 | Derivative | Stock Options (right to buy) | 2023-10-10 | M | D | 114,420 | $0.00 | 48,176 | D | $1.19 · 2016-11-22 to 2023-11-23 | 114,420 Common Stock |